New Mechanism for Treatment of Schizophrenia

Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.

Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on their additional data presentation from the ACNP.

To get a closer look at the Phase 2 EMERGENT-1 poster that was presented at ACNP, see here.

Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.